The University of Southampton
University of Southampton Institutional Repository

Primary mediastinal B-cell lymphoma

Primary mediastinal B-cell lymphoma
Primary mediastinal B-cell lymphoma
Primary mediastinal B-cell lymphoma is a discrete clinicopathologic entity. Molecular analysis reveals it to be distinct from other types of large B-cell lymphoma, and retrospective analysis suggests that it may respond better to multi-agent chemotherapy regimens than to the more commonly used CHOP. The addition of rituximab may mitigate such differences, and may also diminish the role of consolidation radiotherapy, which is often used to treat residual mediastinal masses. For the future the role of FDG-PET scanning requires prospective examination, and it is hoped that this may allow the de-escalation of treatment if it can be shown to yield reliable prognostic information. The relative rarity of this type of lymphoma necessitates international collaboration in clinical trials, with a prospective clinicopathologic study, IELSG 26, already underway.
1520-4391
349-358
Johnson, Peter W.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Davies, Andrew J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Johnson, Peter W.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Davies, Andrew J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af

Johnson, Peter W. and Davies, Andrew J. (2008) Primary mediastinal B-cell lymphoma. Hematology, ASH Education Program, 2008 (1), 349-358. (doi:10.1182/asheducation-2008.1.349). (PMID:19074109)

Record type: Article

Abstract

Primary mediastinal B-cell lymphoma is a discrete clinicopathologic entity. Molecular analysis reveals it to be distinct from other types of large B-cell lymphoma, and retrospective analysis suggests that it may respond better to multi-agent chemotherapy regimens than to the more commonly used CHOP. The addition of rituximab may mitigate such differences, and may also diminish the role of consolidation radiotherapy, which is often used to treat residual mediastinal masses. For the future the role of FDG-PET scanning requires prospective examination, and it is hoped that this may allow the de-escalation of treatment if it can be shown to yield reliable prognostic information. The relative rarity of this type of lymphoma necessitates international collaboration in clinical trials, with a prospective clinicopathologic study, IELSG 26, already underway.

This record has no associated files available for download.

More information

Published date: 1 January 2008

Identifiers

Local EPrints ID: 73250
URI: http://eprints.soton.ac.uk/id/eprint/73250
ISSN: 1520-4391
PURE UUID: 24b13825-5302-4098-9afc-bd2439783606
ORCID for Peter W. Johnson: ORCID iD orcid.org/0000-0003-2306-4974
ORCID for Andrew J. Davies: ORCID iD orcid.org/0000-0002-7517-6938

Catalogue record

Date deposited: 04 Mar 2010
Last modified: 14 Mar 2024 02:54

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×